Please login to the form below

Not currently logged in
Email:
Password:

SMC

This page shows the latest SMC news and features for those working in and with pharma, biotech and healthcare.

SMC enables access to Kyowa Kirin’s Crysvita for rare bone disease

SMC enables access to Kyowa Kirin’s Crysvita for rare bone disease

The SMC evaluated Crysvita under the ultra-orphan pathway, a new system for the consideration of novel treatments for extremely rare diseases. ... After three years, the SMC will review the new evidence and make a final decision on its routine use on NHS

Latest news

More from news
Approximately 15 fully matching, plus 76 partially matching documents found.

Latest Intelligence

  • The Orkambi row explained The Orkambi row explained

    December 2018: Scottish Government agrees a deal with Vertex pending submission of Orkambi and Symkevi to Scottish Medicines Consortium (SMC), with interim access possible through the PACS Tier 2 system.

  • The Orkambi blame game The Orkambi blame game

    Leiden also claimed the breakthrough in Scotland came when NICE’s equivalent, the SMC, agreed to ‘flex’ its methodology – something which he and other industry leaders said is vital if NICE

  • Patient involvement in health technology assessment Patient involvement in health technology assessment

    We have developed a Public Involvement Network (PIN) that formalises relationships with each submitting patient group through a registration process to become an SMC Patient Group Partner. ... SMC as a respected partner in developing and shaping all

  • The reality of real-world evidence The reality of real-world evidence

    Zaltrap re-submission to the Scottish Medicines Consortium (SMC) included RWE (pooled data from two open-label, single-arm studies) to demonstrate prolonged safety and QoL benefit.

  • Charting a course for expansion Charting a course for expansion

    The dossiers are going in and the conversations with NICE and the SMC are happening and we're cautiously optimistic.”.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest from PMHub

  • Recent approval for your brand from NICE or SMC? Time to rethink your market access

    Scottish cost regulators have approved funding for five new therapies on the NHS, offering new treatment options for a range of conditions. Scottish cost regulators have approved funding for five new therapies on the NHS, offering new treatment

  • OUTiCO OUTiCO

    Recent approval for your brand from NICE or SMC? Time to rethink your market access.

  • YorkTown

    decision makers associated with pharmaceutical and medical device/diagnostics market access and HEOR; Developing and writing single technology appraisals (STA) (pharmaceutical and medical device) for regulatory institutions (NICE, EMA, SMC and

  • The Holistic Approach to Market Access

    and to provide local prescribing audit data for inclusion into NICE and SMC technical appraisals the gaining of which is a key element in gaining regional prescribing uptake.

More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency. We dispense pioneering and creative campaigns, driven by...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics